APPLAUSE-IgAN Findings Presented at NKF Spring Clinical Meetings

Joel Topf, MD, of Nephrology Times spoke with Dana V. Rizk, MD, at the National Kidney Foundation Spring Clinical Meetings. Dr. Rizk discussed her study, “Efficacy and safety of iptacopan in patients with IgA nephropathy (IgAN): Interim analysis (IA) of the Phase 3 APPLAUSE-IgAN study.” The phase 3 study seeks to determine the efficacy and safety of iptacopan versus placebo in patients with IgA nephropathy.